Dear editor, Vertebrobasilar ischemic stroke often leads to disabling sequela even if the patient survives. Patients with significant vertebral artery (VA) stenosis (>50%) are at increased risks of recurrent vertebrobasilar stroke and transient ischemic attack (TIA). Endovascular treatment of VA stenosis is available in clinical practice. However, safety and efficacy have not been thoroughly evaluated. Published studies are limited by small cohort size and retrospective study design. The randomized controlled trial (RCT) on safety and feasibility of stenting symptomatic significant VA stenosis was recently published by Compter et al., 1 with emphasis on patients with extracranial vertebral artery stenosis. With a median follow-up of three years, the authors found a higher rate of stroke in the territory of symptomatic VA (12% vs. 7%), any stroke (14% vs. 12%), and the composite outcome (19% vs. 17%) than that in the medical group. As a conclusion, the authors recommended against a phase 3 trial.
A significant limitation of Compter et al. RCT is small sample size (n ¼ 115). 1 Conducting additional prospective trials may be time-consuming and not feasible, so we performed a meta-analysis from current literature with additional data from our local institution to further evaluate the safety and efficacy of stenting symptomatic extracranial VA stenosis of more than 50%.
We included publications from 1999 to 2015 that presented data on the long-term outcomes of patients with significant symptomatic extracranial VA stenosis who underwent either stenting or medical management. [2] [3] [4] [5] Studies with cohort size less than five were excluded. Perioperative complication risk, 30-day event rates, and long-term outcomes such as stroke incidence rate were calculated separately for the stenting and medical management group and compared per data availability. In addition, we compared the proportions of symptomatic patients in stenting versus medical management on long-term follow-up by chi-square. Twenty-eight studies were included in the meta-analysis, 27 studies in the stenting group and 5 in the medical group. Four studies had both. The cohort size was 1552. The median follow-up ranged from 1 month to 56 months, with a total follow-up of 2731 patient-years.
In the stenting group, the rate of perioperative neurologic complications was 1Á1%. Thirty-day event rates were as follows: vascular death 0Á4%, myocardial infarction 0Á7%, TIA 1Á4%, stroke in the VA territory 0%, and any stroke 0%.
At the end of follow-up, patients in the stenting group were less likely to experience any new strokes (incidence rate ratio (INR) ¼ 0Á32, 1.67 vs. 5Á14 per 100 person-year) or any vascular death/myocardial infarction/any stroke (INR ¼ 0Á27, 1Á39 vs. 5Á19 per 100 person-year) than the medical group (Table 1) . Patients in the stenting group were significantly less likely to be symptomatic when compared with patients in the medical group (7Á1% vs. 37Á4%, p < 0.0001). However, the incidence rates for new stroke in VA territory and TIA were not significantly different.
Our meta-analysis demonstrated patients with symptomatic extracranial VA stenosis of more than 50% may benefit from stenting with improved long-term outcomes compared to medical management. Patients with stenting experienced significantly lower new strokes and composite adverse events. The rate of perioperative complications was low. We believe that a larger RCT is warranted to evaluate the efficacy of stenting in this subset of patients. International Journal of Stroke, 11 (2) Wang et al. NP23
